Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)
Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.
1 finding from 1 review
- no estimate extracted1 study · 460 participantsModerate